Proposed Final Judgment in US antitrust case against Live Nation Entertainment requires the company to divest certain assets and comply with operational restrictions affecting ticket sales and venue management; final judgment pending court approval.
FDA determines that vasopressin 0.9% injection was not withdrawn for safety or effectiveness reasons, allowing approval of generic abbreviated new drug applications if other regulatory requirements are met.
Tell Bizmoon what your business does and we'll cut the Federal Register down to what actually matters.
Every rule is broken into specific to-dos with calendar dates.
We tell you which parts of your business each rule actually touches.
After healthcare come the capital-heavy sectors: trade, transportation, energy, and finance. If you operate in one of them, the volume of change is relentless.
Centers for Medicare & Medicaid Services launches a matching program with the Department of Veterans Affairs to verify eligibility for insurance affordability programs under the Affordable Care Act.
New York's Administrative Declaration of Disaster dated June 30, 2026, covers severe storms and flooding and may trigger state and federal disaster assistance programs for affected small businesses.
NIH requests 60-day public comment on proposed data collection for citizen science and crowdsourcing projects under Paperwork Reduction Act review; deadline is 60 days from publication.
The Drug Enforcement Administration announces temporary scheduling of mitragynine pseudoindoxyl, MGM-15, and MGM-16 as Schedule I controlled substances, restricting manufacturing, distribution, possession, and research activities.
EPA accepts public comments on new pesticide product registration applications containing previously unregistered active ingredients, with details on 2025 submissions under Federal Insecticide, Fungicide, and Rodenticide Act procedures.
EPA received pesticide product registration applications for new uses of currently registered active ingredients and solicits public comments on the April 2026 compilations.
The FDA seeks OMB clearance for information collection procedures related to premarket approval of medical devices under the Paperwork Reduction Act.
CMS proposes 2027 Medicare home health payment rate updates, case-mix recalibrations, quality reporting changes, and DMEPOS enrollment and benefit modifications affecting home health agencies and DME suppliers.
No legal jargon. Read the impact in two sentences.
Email + dashboard pings the moment something changes.
